Liquidia Corporation (LQDA)

Market Cap	2.15B
Revenue (ttm)	19.32M
Net Income (ttm)	-152.32M
Shares Out	85.48M
EPS (ttm)	-1.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,128,939
Open	24.85
Previous Close	24.10
Day's Range	23.83 - 25.31
52-Week Range	8.26 - 25.31
Beta	0.15
Analysts	Strong Buy
Price Target	30.11 (+19.48%)
Earnings Date	Aug 12, 2025

About LQDA

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 26, 2018
• Employees: 170
• Stock Exchange: NASDAQ
• Ticker Symbol: LQDA
• Website: https://www.liquidia.com

Financial Performance

In 2024, Liquidia's revenue was $14.00 million, a decrease of -19.97% compared to the previous year's $17.49 million. Losses were -$130.39 million, 66.1% more than in 2023.

Analyst Forecast

According to 9 analysts, the average rating for LQDA stock is "Strong Buy." The 12-month stock price target is $30.11, which is an increase of 19.48% from the latest price.

Price Target

$30.11

(19.48% upside)

Analyst Consensus: Strong Buy